Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.57 |
| ▸ | CTSL | P07711 | 11/20 | 0.57 |
| ▸ | CTSS | P25774 | 7/20 | 0.57 |
| ▸ | CTSB | P07858 | 4/20 | 0.57 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.46 |
| ▸ | CTSV | O60911 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745635 | 0.91 | CTSK (0.49) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL14345772 | 0.86 | CTSK (0.64) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL5744937 | 0.86 | TAS1R3 (0.64) | CTSKCTSLCTSBTAS1R3TAS1R1 | |
| SCHEMBL5744609 | 0.80 | CTSK (0.70) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL4690508 | 0.79 | CTSK (0.74) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL4765813 | 0.78 | CTSK (0.73) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL4689513 | 0.78 | CTSK (0.67) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4690381 | 0.77 | CTSK (0.75) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL6589430 | 0.76 | CTSK (0.55) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL5744626 | 0.76 | CTSK (0.49) | CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358183-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | CTSK 4/4885CTSL 10/4885CTSS 2/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | CTSK 5/4885CTSL 13/4885CTSS 3/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | CTSK 3/4885CTSL 9/4885CTSS 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.